---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-039201"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:07:35.895065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cyclerion Q2 net loss $16.2M; cash $70M; pipeline advances; praliciguat licensed to Akebia for up to $585M milestones

## Summary
- Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.
- CY6463 Phase 2a trial initiated in Alzheimer's with vascular pathology (ADv); Ph1b in CIAS start-up; MELAS data expected by year-end 2021.
- Exclusive global license of praliciguat to Akebia Therapeutics; Cyclerion eligible for up to $585M milestones plus tiered royalties.
- Closed $18M private placement with EcoR1, Slate Path, MFN, Invus, and others; net $12.5M from ATM offering in Q2.
- Errol De Souza appointed to Board of Directors; expanded Beacon Biosignals partnership for biomarker identification.

## SEC filing metadata
- accession: 0001564590-21-039201
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/0001564590-21-039201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/cycn-8k_20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-039201
- JSON: https://secwatch.observer/filing/0001564590-21-039201.json
- Plain text: https://secwatch.observer/filing/0001564590-21-039201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.